by RT-PCR. The levels of c-fos and NFATC1 protein were assessed by western blot. Also the mitogen-activated protein (MAPK)s and important signal pathways were measured using Western blot analysis. Osteoclast function was evaluated with resorption pit assay and osteoblastic effects of Cldn11 was evaluated with new bone formation of mouse calvaria. With LPS and co-treated Recombinant protein of Cldn11 on mouse calvaria, we evaluated the effects of Cldn11 on LPS induced bone loss by using histologic analysis.

**Results:** We found that Cldn11 played a negative role in receptor activator of nuclear factor kappa B ligand dependent osteoclast (OC) differentiation by down-regulating the phosphorylated form of extracellular signal-regulated kinase (ERK).

Bruton’s tyrosine kinase, and phospholipase C gamma 2, in turn impeding c-Fos and nuclear factor of activated T cells c1 expression. Osteoblast (OB) differentiation by positive feedback of Cldn11 was achieved through the phosphorylation of Smad1/5/8, ERK, and c-Jun amino-terminal kinase. Importantly, this Cldn11-dependent dual event arose from targeting EphrinB2 ligand reverse signalling into OC and EphB4 receptor forward signalling into OB. In agreement with these in vitro effects, subcutaneous injection of Cldn11 recombinant protein exerted similar effects on local calvarial regions in mice.

**Conclusions:** These findings suggest that Cldn11 is a novel regulator in bone homeostasis.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.3828

---

**OP0265**

**LOCAL REACTIVATION OF GLUCOCORTICOIDS BY 11B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 MEDIATES THE DEVELOPMENT OF GLUCOCORTICOID-INDUCED BONE LOSS**

C Fenton1,2, C Doig1, S Fared3, A Naylor3, C Wehmeyer3, C Buckley3,
G Lavery1, M Cooper3, K Rajpoot3, R Hardy1. 1Institute of Metabolism and Systems Research; 2Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; 3ANZAC Research Institute, University of Sydney, Sydney, Australia

**Background:** Due to the potent immunomodulatory and anti-inflammatory nature of glucocorticoids (GCs) they are routinely used in the treatment of inflammatory diseases such as rheumatoid arthritis. However their therapeutic potential is limited due to the prevalence of adverse side effects associated with long term GC exposure such as osteoporosis, insulin resistance and obesity. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a bi-directional enzyme that primarily converts inactive GCs to the active counterparts. Previously, local reactivation of GCs by 11β-HSD1 has been shown to play a major role in the metabolic side effects associated with GC excess.

**Objectives:** We aim to assess whether local reactivation of GCs by 11β-HSD1 mediates the adverse effects of therapeutic GCs on bone.

**Methods:** Wild-type (WT) mice and transgenic mice with a global 11β-HSD1 knockout (11β-HSD1 KO) were treated with the active murine GC corticosterone (CORT) (100 mg/ml) for 4 weeks. Tibia and humerus bones were excised post-mortem for micro-CT analysis, gene expression analysis and three point flexure strength (TFS) tests. Serum was collected from mice for ELISA analysis of TRAcP-5b and P1NP.

**Results:** Micro-CT analysis of bone volume to tissue volume (BV/TV), trabecular thickness (TT) and trabecular number (TN) found no significant differences between untreated WT and 11β-HSD1 KO mice (BV/TV: WT 8.5±0.06 vs 11β-HSD1 KO 7.5±0.76, NS; TT: WT 96.5±3.8 vs 11β-HSD1 KO 95.8±6.4, NS; TN: WT 0.0009 1/µm±0.0004 vs 11β-HSD1 KO 0.0008 1/µm±0.0004, NS). Humerus TFS tests of WT and 11β-HSD1 KO animals also showed no significant differences (WT 51.2 MPa±15.1 vs 11β-HSD1 KO 49.2 MPa±4.9, NS). All bone parameters were decreased in CORT fed WT mice indicating the development of osteoporosis, whilst 11β-HSD1 KO mice were protected against many of the detrimental effects of CORT (BV/TV: WT 4.2±0.38 vs 11β-HSD1 KO 7.2±0.71, p<0.05; TN: WT 0.0006 1/µm±0.0004 vs 11β-HSD1 KO 0.0009 1/µm±0.0008, p=0.001; HBS: WT 27.1±5.6 vs 11β-HSD1 KO 50.5 MPa±5.1, p=0.05). ELISA analysis of mouse serum showed no significant differences in the bone resorbing osteoclast marker TRAcP-5b amongst the groups, whereas analysis of the bone forming osteoblast marker P1NP revealed a significant increase in CORT fed 11β-HSD1 KO mice compared with CORT fed WT mice (11β-HSD1 KO 158.6 ng/ml±53.1 vs WT 31.4 ng/ml±7.4, p=0.05). Gene expression of the mature osteoblast markers ALP (alkaline phosphatase) and BGLAP (osteocalcin) showed significant increases in CORT fed 11β-HSD1 KO animals compared to CORT fed WT animals (ALP: 11β-HSD1 KO 0.0074 AU±0.0012 vs WT 0.0022 AU±0.0007, p<0.01; BGLAP: 11β-HSD1 KO 0.27 AU±0.04 vs WT 0.02 AU±0.01, p<0.001).

**Conclusions:** These data suggest that local reactivation of GCs by 11β-HSD1 mediates the development of glucocorticoid-induced osteoporosis by inhibiting osteoblastic bone formation.

**REFERENCE:**